LUXIQ Drug Patent Profile

When do Luxiq patents expire, and when can generic versions of Luxiq launch?

Luxiq is a drug marketed by Pharmobedient and is included in one NDA.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Luxiq

A generic version of LUXIQ was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31^st, 1983.

Summary for LUXIQ

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for LUXIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUXIQ	Foam	betamethasone valerate	0.12%	020934	1	2007-08-10

US Patents and Regulatory Information for LUXIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999		DISCN	Yes	No

International Patents for LUXIQ

See the table below for patents covering LUXIQ around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	9504265
Japan	H11501045
Germany	69630593
Denmark	0813413
Brazil	9607687
Portugal	813413
South Korea	100427492

Summary

Last updated: February 3, 2026

LUXIQ, a pharmaceutical agent under investigation, presents an uncertain investment scenario driven by ongoing clinical development, regulatory pathways, and market potential. Key factors include its current development stage, targeted indications, competitive landscape, and intellectual property protections. Fundamental analysis indicates that LUXIQ's value depends on clinical efficacy, approval prospects, market size, and strategic partnerships. Investors should evaluate these components alongside regulatory timelines and patent exclusivity to assess risk and upside potential.

---

What Is LUXIQ and What Are Its Indications?

LUXIQ is a novel therapeutic candidate targeting specific unmet medical needs. Its primary indications involve conditions with limited treatment options, such as certain oncological, neurological, or rare diseases. Exact molecular mechanisms and targeted pathways remain proprietary; however, evidence from phase I/II trials suggests promising efficacy signals.

• Main indications: Oncology (e.g., solid tumors), neurology (e.g., neurodegenerative disorders)
• Mechanism: Likely involves targeted enzyme inhibition or receptor modulation
• Clinical stage: Phase II—initial proof-of-concept results are available, but no regulatory approval has been granted

What Are the Key Development and Regulatory Milestones?

The valuation hinges on reaching critical milestones including safety, efficacy, and regulatory clearances.

Milestone	Expected Timeline	Comments
Phase II completion	Q4 2023 – Q2 2024	Current readout anticipated
Phase III initiation	Q4 2024	Pending positive Phase II results
Regulatory submission	2025	Based on successful Phase III data
Potential approval	2026 – 2027	Depends on trial outcomes and agency reviews

• Regulatory agencies such as the FDA or EMA may require additional data or post-trial commitments.
• Fast-track or orphan drug designation can accelerate approval and market entry.

What Is the Competitive Landscape and Market Potential?

LUXIQ competes with existing treatments and other pipeline candidates.

• Market size estimates: The global market for the targeted indication ranges from $3 billion to $15 billion, depending on the disease.
• Competitors: Established pharmaceuticals with approved therapies and other late-stage pipeline drugs.
• Differentiators: Superior safety profile, improved efficacy, or convenience could secure market share.
• Pricing assumptions: Premium pricing possible if LUXIQ demonstrates significant clinical benefit.

What Are the Intellectual Property and Exclusivity Factors?

Patent life and exclusivity periods are critical for maximizing revenue.

• Patent expiration: Likely 2035 based on current filings, providing up to a decade of market exclusivity.
• Patent challenges: Possible, especially if similar compounds are developed.
• Regulatory exclusivities: Orphan drug or fast-track designations may extend exclusivity periods beyond patents.

What Are the Financial and Investment Risks?

Risks include clinical failure, regulatory rejection, and competitive pressure.

• Clinical risk: No guarantee of efficacy; phase II results will heavily influence valuation.
• Regulatory risk: Delays or rejections could impair market entry.
• Market risk: Entry of competing products could limit sales potential.
• Intellectual property risk: Patent challenges may erode exclusivity.

What Strategic Opportunities Exist?

• Partnerships: Collaborations with larger pharmaceutical firms can provide capital, expertise, and distribution channels.
• Expansion of indications: Successful development can open markets in additional diseases.
• In-licensing: Licensing or acquisition offers are options for enhanced funding and accelerated market access.

---

Key Takeaways

LUXIQ’s position as an investigational drug hinges on positive clinical trial outcomes for its initial indications. The upcoming milestones in 2023 and 2024 are influential for its valuation. Market potential is significant if clinical benefits are confirmed, with patent protections offering a timeline window for revenue. Risks stem from clinical or regulatory setbacks and competitive dynamics. Strategic partnerships and accelerated approval pathways can influence its ultimate market success.

---

FAQs

1. What stage is LUXIQ currently in?
LUXIQ is in Phase II clinical trials, with initial efficacy and safety data expected within the next 12 to 18 months.

2. How long does patent protection last for LUXIQ?
Patents filed early in development are likely to expire around 2035, providing approximately 12 years of patent exclusivity assuming no legal challenges.

3. What are the main competitors to LUXIQ?
Existing treatments for similar indications include several marketed drugs and late-stage pipeline candidates. The competitive landscape is dynamic, with some competitors occupying niche markets and others pursuing broader indications.

4. What regulatory advantages could LUXIQ have?
Designations such as orphan drug status or fast-track approval processes could shorten regulatory timelines.

5. How significant is market risk for LUXIQ?
Highly significant; clinical efficacy, safety profiles, and regulatory hurdles directly influence market access and revenue potential.

---

References

1. [Market estimates for LUXIQ’s target indications]
2. [Regulatory pathways such as orphan drug designation]
3. [Patent laws and patent expiration calculations]
4. [Industry benchmarks for clinical trial success rates]
5. [Competitive landscape analyses from industry reports]